1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Goldenwell Biotech, Inc.

Goldenwell Biotech, Inc.

GWLL
Goldenwell Biotech, Inc.US flagOther OTC
0.90
USD
- -
- -
89.10MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
-0.01
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-0.01
-0.01
-0.01
-0.02
-0.02
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
96
91
96
99
99
99
98
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-740.7
-2,060.89
-6,308.61
-88,559.71
-206,047.27
-196,772.73
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-1
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-732.64
-2,060.87
-6,392.21
-94,602.88
-539,038.18
-500,983.64
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
20
283
98

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
80.3%
627.57%
Free Cash Flow
- -
680.87%
-81.61%
Net Income, GAAP
- -
508.26%
125.46%
Sales/Revenue/Turnover
- -
- -
-60.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Shuang Liu
Full Time Employees
3
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
581 Boston Mills Road Hudson OH United States of America 44236
IPO Date
Sep 30, 2022
CIK
0001800373
Website
goldenwellbiotech.com
Similar Companies
SSY Group Limited (2005.HK)
Matrix Denture Systems International, Inc (MDSI)
Roopa Industries Limited (ROOPAIND.BO)
FDC Limited (FDC.BO)
Organon Pharma Indonesia PT (SCPI.JK)
Phaarmasia Limited (PHRMASI.BO)
Business
Goldenwell Biotech, Inc. (GWLL) develops and manufactures nutraceutical and dietary supplements in the United States. The company offers JI MAI, a bovine cardiac vascular active peptide; Cartilage Peptide, a type II collagen peptide; Double Proline AG 3D active collagen peptide; DNA repair tablets; and Sugar Master tablets. Goldenwell Biotech, Inc. operates in the personal care products industry within the household sector, targeting health-conscious consumers with peptide-based supplements for vascular health, joint support, skin care, cellular repair, and blood sugar management. Founded in 2019 and headquartered at 581 Boston Mills Road, Suite 300, Hudson, Ohio 44236, the company maintains customizable manufacturing facilities to ensure product quality and holds international and domestic technology patents. No major acquisitions, partnerships, funding rounds, or product launches have been publicly reported in the last 1-2 years.